https://www.selleckchem.com/products/az628.html Contrary to initial assumptions, selective Caspase-3 inhibitors have not reached the clinical level, while QPI-1007, a siRNA directed against Caspase-2, is currently undergoing a multicentric phase III clinical study for the treatment of ischemic optic neuropathies.Cellular senescence has been now shown to be at the root of many degenerative processes that characterize ageing. Thus, in addition to an irreversible proliferative arrest following various stresses or inappropriate stimuli, cellular senescence leads to genetic, epigenetic, metabolic, structural and functional adaptations of the cell. Moreover, senescence phenotype spreads to the surrounding tissue through a specific secretory profile. Eliminating or blocking the action of senescent cells by senotherapeutic agents prevents tissue degeneration and improves the longevity in preclinical models. In this review, we will present the latest applications in senotherapy and discuss the very promising results of the first recently published clinical trials.Health is harmony, aging and its diseases (are) functional disharmony at the molecular, cellular and tissue levels. Our observations lead us to think that there seems to be a common cause and a common mechanism for aging and its many and diverse diseases. This common cause is the oxidative damage to particular proteins emerging from a combination of imperfect folding and oxidative stress. This common cause jointly goes with the biological clock common to various age-related diseases, whose the incidence increases exponentially over time and causes 90% of human mortality. Pharmacological interventions on the common cause could avoid and simultaneously attenuate all degenerative and malignant diseases, as it is the natural case of super-centenarians.The accumulation of senescent cells accompanies organismal aging. Senescent cells produce an inflammatory microenvironment that is conducive to the development of many age